CURE Pharmaceutical Letter to Shareholders
15 Dec 2022 //
ACCESSWIRE
CURE Pharmaceutical Reports Third Quarter 2022 Results
22 Nov 2022 //
ACCESSWIRE
Cure Pharmaceutical Reports Second Quarter 2022 Results
02 Sep 2022 //
GLOBENEWSWIRE
CURE Pharma Announces Rob Davidson & Rob Costantino as board members
16 Aug 2022 //
GLOBENEWSWIRE
CURE Pharmaceutical Provided Full Corporate Update on Recent Shareholder Call
09 Aug 2022 //
GLOBENEWSWIRE
Cure Pharmaceutical sells drug delivery patents in $20M deal
02 Aug 2022 //
FIERCEPHARMA
CURE Pharmaceutical Announces Teleconference With Investors
01 Aug 2022 //
GLOBENEWSWIRE
CURE Pharma Announces Sale of a Portion of its Platform Technology IP for $20M
28 Jul 2022 //
GLOBENEWSWIRE
CURE Pharma Announces Positive Findings from Study Using CURE`s Vitamin D
12 May 2022 //
GLOBENEWSWIRE
CURE Pharma and Mila ro Pharma Collaborate for Sildenafil Oral Thin Film
03 Mar 2022 //
GLOBENEWSWIRE
CURE Pharmaceutical Receives Patent Approval for Its CUREfilm Blue Technology
16 Nov 2021 //
BUSINESSWIRE
CURE Pharmaceutical reports second quarter 2021 revenue; sees rise of 700%.
17 Aug 2021 //
BUSINESSWIRE
CURE Pharmaceutical to Present at H.C. Wainwright 2021
15 Jun 2021 //
BUSINESSWIRE
CURE Pharmaceutical Signs Agreement to Develop CBD and THC Oral Thin Films
10 Jun 2021 //
BUSINESSWIRE
CURE Pharmaceutical Announces Successful Results From Initial Clinical Trials
21 Apr 2021 //
BUSINESSWIRE
CURE Pharmaceutical Reports Increase in Revenue to $7.7 Million
01 Apr 2021 //
BUSINESSWIRE
CURE Launches Psychedelic Oral Film Program Targeting Mental Health
16 Mar 2021 //
BIOSPACE
CURE Launches Psychedelic Oral Film Program Targeting the Treatment
16 Mar 2021 //
BUSINESSWIRE
CURE Announces the Initiation of Clinical Trials for Erectile CUREfilm Blue™
23 Feb 2021 //
BUSINATSSWIRE
CURE Pharmaceutical Announces the Initiation of Clinical Trials for Erectile
23 Feb 2021 //
BUSINATSSWIRE
CURE Receives FDA Approval for its IND Application for Erectile CUREfilm Blue™
05 Jan 2021 //
BIOSPACE